Nov 26, 2024 IPOs in Life Sciences By James Baillieu Fiona McFarlane The amount of capital required to develop and bring a drug to market is significant. It is estimated that it costs US$1-2 billion to...
Nov 13, 2024 M&A in Life Sciences By James Baillieu Companies in the life sciences sector and its sub-sectors, including pharmaceuticals, medical devices, diagnostics and services, are...
Nov 04, 2024 Licensing and Collaborations in Life Sciences By James Baillieu Sally Shorthose There is a huge cost of bringing a pharmaceutical product to market, with estimates ranging from US$1-2 billion to take a product from...
Oct 18, 2024 Venture Capital and Venture Debt in Life Sciences By James Baillieu In recent decades, venture capital (VC) has played an increasingly important role in the high-risk and high-reward life sciences sector....
Oct 14, 2024 Fight against medicine shortages: the French Medicines Agency (ANSM) imposes fines totalling €8 million By Caroline Arrighi-Savoie Johanna Harelimana Nahla Ghouali On 24 September, the French National Agency for the Safety of Medicines and Health Products (ANSM) announced fines totalling €8 million...
Oct 09, 2024 Case C-237/22 of the CJEU – Clarification of the concepts of “Significant Benefit” and “Clinical Superiority” By Marc Martens Benedicte Mourisse The CJEU brings clarity, on the concepts of “Significant Benefit” and “Clinical Superiority” with respect to Orphan Medicinal Products...
Oct 02, 2024 Navigating the Complex Landscape of Merger Control and Foreign Direct Investment in Life Sciences in the EU and UK By James Baillieu Dr Saskia King In the rapidly evolving world of life sciences, merger control and foreign direct investment (“FDI”) regimes have emerged as key...
Sep 30, 2024 EU VAT: Novo Nordisk ruling unlocks VAT refund benefits for pharma companies – key takeaways By Andy van Esdonk On September 12, 2024, the Court of Justice of the European Union (CJEU) delivered a ruling in a case involving Novo Nordisk AS...
Sep 19, 2024 EU Parliament Adopts Position on Pharmaceutical Reform: implications for the Environmental Risk Assessment By Hester Borgers Emma Stok In our earlier article, we discussed the implications of the European Commission’s legislative proposal from 26 April 2023 for the...
Sep 05, 2024 What do the Political Guidelines for the Next European Commission bring to the life sciences & healthcare industry? By Hester Borgers Ana-Maria Barbu-Nyström On 18 July 2024 President Von der Leyen laid down the path for the next European Commission in her Political Guidelines for the next...
Aug 27, 2024 Clinical Trial Update in Ireland: New model Clinical Trial Agreement for Tripartite Clinical Trials in Ireland By Kelly Mackey Earlier this summer, the Irish Pharmaceutical Healthcare Association (IPHA), which represents the international originator...